news
press releases
13 Mar 13 - University of Modena and Reggio Emilia implant Italy’s first patients with Sequana Medical’s alfapump system
Swiss company’s innovative technology for the management of refractory ascites significantly reduces the need for large-volume paracentesis
30 Oct 12 - Sequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites
Innovative implantable pump system set to benefit patients with ascites caused by cancer
23 May 12 - University Hospital Zurich and University Inselspital Berne implant their first patients with Sequana Medical’s ALFApump® System
Swiss company’s innovative technology for the management of refractory ascites significantly reduces the need for large-volume paracentesis, improving patient quality of life
20 Apr 12 - Sequana Medical’s ALFApump® System proves to be a safe and efficacious breakthrough technology in ascites management
Data presented at the International Liver Disease Meeting
01 Mar 12 - Sequana Medical’s ALFApump® System receives reimbursement in Germany for breakthrough technology in ascites management
NUB grants approval for fifteen leading hepatology centres in Germany
30 Jan 12 - Sequana Medical has been selected as a finalist for the 2012 MEDTEC EMDT Innovation Awards
Sequana Medical from Zürich, Switzerland has been nominated for one of the European medical-device industry’s most prestigious awards.
09 Dec 11 - NHS National Innovation Centre estimates Sequana Medical’s ALFApump® System could save the NHS £50 million in ascites care annually
NHS National Innovation Centre supports the cost effectiveness of Sequana Medical’s ALFApump System.
04 Nov 11 - First Commerical Implants
The Medical University of Vienna and Vienna General Hospital perform the first two commercial implants worldwide of Sequana Medical’s ALFApump® System.
13 July 11 - Sequana Medical receives CE Mark Approval for the ALFApump® System and adds Key Executive to Team
New technology expands treatment options for patient with refractory ascites due to liver cirrhosis.
Dr.Farzana Malik joins as Vice President of Market Access and Reimbursement.
30 May 11 - NovaShunt announces the launch of its new corporate identity: Sequana Medical
NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana MedicalAG (www.sequanamedical.com) as it prepares for the upcoming launch of the ALFApump® System in Europe...